Thanks for the link, opened fine for me. Cytodyn mentioned prominently in the 2Q presentation and appears to be positioned/groomed as a valuable revenue asset for BIOMM who's needing - ahem - a shot in the arm-

CYDY also mentioned a couple of times in the 68 page formal filing-